CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 145 enrolled
Drug / intervention
Testosterone Gel (FE 999093)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01703741
NCT01703741Phase 3Completed
CompareCT.gov

A Multicenter Extension Trial to Evaluate the Safety of FE 999303 (Testosterone Gel) in Adult Hypogonadal Males

Ferring Pharmaceuticals·interventional·Posted Oct 10, 2012·Updated Oct 6, 2017

In Brief

A Phase 3 clinical trial evaluating Testosterone Gel (FE 999093) for Adult Male Hypogonadism. Completed, enrolled 145 participants across 18 sites in 2 countries.

Detailed Summary

This is a multicenter extension trial in adult hypogonadal males. The purpose of this study is to evaluate the safety of testosterone gel delivered using an applicator over an extended period of time.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdult Male Hypogonadism
CountriesCanada, United States
Collaborators--

Timeline

Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedOct 10, 2012
Enrollment StartDec 1, 2012
Primary CompletionOct 1, 2013
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 13.7 years ago

Interventions

Testosterone Gel (FE 999093)drug